US Patent 10280172 Inhibitors of KRAS G12C mutant proteins

Is a

Patent

Patent attributes

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

102801720

Patent Inventor Names

Yuan Liu0

Liansheng Li0

Pingda Ren0

Yi Liu0

Yun Oliver Long0

Jun Feng0

Date of Patent

May 7, 2019

Patent Application Number

157210210

Date Filed

September 29, 2017

Patent Citations Received

‌

US Patent 12134620 Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer

‌

US Patent 10975071 Inhibitors of KRAS G12C mutant proteins

‌

US Patent 11021470 2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof

‌

US Patent 11059819 Fused hetero-hetero bicyclic compounds and methods of use thereof

‌

US Patent 11639346 Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS

‌

US Patent 11274093 Fused bicyclic benzoheteroaromatic compounds and methods of use thereof

‌

US Patent 11279689 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer

‌

US Patent 11358959 Benzothiophene and benzothiazole compounds and methods of use thereof

...

Patent Primary Examiner

‌

Niloofar Rahmani

Patent abstract

Compounds having activity as inhibitors of G12C mutant KRAS protein are provided. The compounds have the following structure (I):

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

US Patent 10280172 Inhibitors of KRAS G12C mutant proteins

Contents

Patent attributes

Timeline

Further Resources

References

Find more entities like US Patent 10280172 Inhibitors of KRAS G12C mutant proteins